Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia
NCT04909333Completed
- Sponsor
- University Hospital Basel
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of exenatide in endogenous hyperinsulinemic hypoglycemia (3 arms), sponsored by University Hospital Basel. Primary endpoint: Time to symptomatic hypoglycemia after exenatide test compared to placebo at 4 hours. Started Apr 2021; status: completed.
02
Drugs
exenatide
03
Conditions
endogenous hyperinsulinemic hypoglycemia
Beyond the preview
Go deeper on NCT04909333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04909333.